This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024) |
Pharmaceutical compound
Clinical data | |
---|---|
Other names | AG-7404, V-7404 |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H29N5O7 |
Molar mass | 523.546 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Imocitrelvir is an investigational new drug that is being evaluated for the treatment of viral infections. It is a 3C protease inhibitor in picornaviruses. Originally developed by Pfizer for treating human rhinovirus infections, this small molecule has shown promise against a broader range of viruses, including polioviruses.
References
- "Imocitrelvir". PatSnap.
- Xie H, Rhoden EE, Liu HM, Ogunsemowo F, Mainou BA, Burke RM, et al. (November 2024). "Antiviral Development for the Polio Endgame: Current Progress and Future Directions". Pathogens. 13 (11). Basel, Switzerland: 969. doi:10.3390/pathogens13110969. PMC 11597170. PMID 39599522.
- Bandyopadhyay AS, Burke RM, Hawes KM (June 2024). "Polio Eradication: Status, Struggles and Strategies". The Pediatric Infectious Disease Journal. 43 (6): e207-211. doi:10.1097/INF.0000000000004330. PMID 38564755.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |